Galectin Therapeutics Inc. · NASDAQ:GALT
Galectin Therapeutics — Investor Presentation (January 2014)
35 slides from Galectin Therapeutics's investor presentation, Jan 13, 2014
Slide 1: Corporate Presentation January 2014
Exhibit 99.1 Exhibit Corporate January NASDAQ: © Therapeutics NASDAQ:GALT 2014 99.1 Galectin 2014 Presentation GALT www.galectintherapeutics.com
Slide 2: Forward Looking Statements
Forward This the Private current regarding benefits impacted approval consuming competition Plans Estimates any effective. complete date, discussion Although 2© 2014 meaning such presentation we regarding expectations Securities Galectin of have Looking are drugs, future by Our subsequent drugs rega
Slide 3: The Agenda
The Agenda Galectin Fibrosis 3© 2014 Company Galectin Program Inhibitors and Therapeutics –Key our primary Team Members NASDAQ:GALT focus Cancer Immunotherapy Summary
Slide 4: What Galectin Therapeutics Does
What Clinical Galectin Currently Liver 4© 2014 We fibrosis Galectin stage proteins Do in clinical indication: biopharmaceutical Therapeutics aretrials important NASH in liver NASDAQ:GALT in(Fatty company fibrosis the development Liver and targeting Disease) cancer and fibrotic with promotion advance
Slide 5: Key Corporate Facts
Key Trading Corporate Stock Shares Daily Market Debt Cash Estimated Fiscal Accounting 5© 2014 Facts $0 &Volume Price; Year Outstanding Capitalization Galectin Equivalents Symbol Headquarters Spending –Ends Firm As 52(50 of Week Nasdaq: Therapeutics December McGladrey day January 20.7 $32.3 inRange $
Slide 6: Experienced Leadership Team
Experienced James Peter Harold COO Jack Secretary Eliezer J. Development Pharmaceutical Executive Regulatory Quality Manager GlaxoSmithKline Solvay CFO Koor Over Director 6© Rex 2014 W. Reach 28 32 30 24 G. Biotechnologies, &Czirr, Horton H. Pharmaceuticals Zomer, Assurance Galectin Callicutt Corpor
Slide 7: The Agenda
The Agenda Galectin Fibrosis 7© 2014 Company Galectin Program Inhibitors and Therapeutics –Key our key Teamfocus Members NASDAQ:GALT Cancer Immunotherapy Summary
Slide 8: Galectins and Galectin Inhibitors Function
Galectin Galectins Function Galectin-3 Under levels Our Galactomannan Galacto-rhamnogalaturonate Discovery Derivatives 8© 2014 proprietary of normal Galectin family galectin-3 through Inhibitors bind pipeline isofwidely physiological GM via drugs (15 (GM) Therapeutics binding their and members) expr
Slide 9: Intellectual Property
Intellectual GM-CT US Five (expires GR-MD Composition pending Sole 9© 2014 Composition USGalectin ownership Class 2026) (priority issued Class Property of(current (current Multiple method of matter Therapeutics of 2011) compounds matter NCE patent NCE of Method method use patent is ispending patents
Slide 10: The Agenda
The Agenda Fibrosis Cancer © 10 2014 Company Immunotherapy Galectin Program andTherapeutics –Key our key Team Summary focus Members NASDAQ:GALT Galectins and Disease
Slide 11: Fundamental Role of Galectin-3 in Fibrosis
Fundamental Red Mice No Normal Henderson, Galectin-3 Fatty © 11 2014 gal-3 stain treated liver Galectin mouse mice mouse isdisease null et collagen, with Science develop almice 2006 Therapeutics liver Kidney (no are the on fibrosis toxin also galectin-3) Target principal fibrotic to resistant wherea
Slide 12: Galectin Inhibitors Reverse Cirrhosis in Rat Model
Company’s Animal Percent V 10 20 30 40 P<0.0001 P<0.001 Vehicle Broad Reduction © 12GR 2014Gm bands Collagen GR-MD-02 model Galectin inGalectin of collagen presented collagen Therapeutics GM-CT-01 Inhibitors with with a very thin nodule NASDAQ:GALT Reverse high and broken hurdle formation Cirrhosis
Slide 13: GR-MD-02 in Mouse Model of NASH with Fibrosis
Galectin Fat GR-MD-02 Control X200 Red © 13 2014 Cell = Collagen Galectin death Inhibitor GR-MD-02 Inflammation Therapeutics GR-MD-02 NASDAQ:GALT Improved Fat, Liver Cell Death, Inflammation, and Fibrosis in Mouse Model of Fatty Liver Disease (NASH) with Fibrosis
Slide 14: Potential Use of GR-MD-02 in Lung Fibrosis
514 Potential Lung Ashcroft 10P Normalfibrosis 43 <0.0001 2Score Useofin Bleo/GR-MD-02 Bleo/Vehicle Saline P<0.05 Large Marked © 2014 areas induced Galectin Vehicle reductionLung Fibrosis: byfibrosis. confluent GR-MD-02 tracheal Therapeutics in area GR-MD-02 instillation and severity NASDAQ:GALT Red
Slide 15: Potential Use of GR-MD-02 in Kidney Fibrosis
Potential Sirius 2.0 0.0 0.5 1.0 1.5 Arrows GR-MD-02 Vehicle X200 Normal Reduction © 15 2014 p<0.05 red-positive GR-MD-02 show Galectin Use inReduces interstitial in areas Kidney Therapeutics area ofFibrosis interstitial (%) fibrosis Fibrosis: in NASDAQ:GALT Diabetic fibrosis Mouse
Slide 16: Liver Fibrosis: Multiple End Stage Diseases
Liver Multiple End There First Prevalence NASH © 16 2014 stage indication Fibrosis iscirrhosis (Non-Alcoholic Galectin no liver fibrosis, of approved NASH diseases Development isprojected Therapeutics fatty or in medical cirrhosis, lead liver SteatoHepatitis) U.S. toto disease Program be istherapy f
Slide 17: NASH Fibrosis Development Program: Accomplishments
NASH New well GR-MD-02 GMP Studies FDA completed. © 17 2014 as strategic review drug with reduction completed Galectin substance Data more Fibrosis offocus: IND to Therapeutics in effective in be inflammation for 2011 Development and multiple reported GR-MD-02 product Annual thanspecies NASDAQ:GALT
Slide 18: Development Program: Targeting Late Stage NASH
Development Obesity/Insulin Decades Steatosis NASH Stage Fibrosis Clinical Early No Because © 18 2014 certainty Disease 1(inflammation, 2Galectin Outcomes Cirrhosis of (fatty 3 effect Stage ofProgram: Late liver) progression Resistance/Diabetes Therapeutics on 4Complications Disease inflammation cel
Slide 19: Phase 1 Clinical Trial Design by Dose
Phase by Dose: Primary Patient Pharmacokinetics Exploratory data Cohort © 19 2014 three from 1safety Starting inclusion: 1: 2: 3: Galectin Clinical endpoints: additional Mar-Apr Jul-Aug Oct–Nov each serum dose cohort Trial Therapeutics Biopsy Secondary 2014 biomarkers weekly 2014 2014 of 2 mg/kg pro
Slide 20: Key Biomarkers for Assessing Potential Efficacy
Key ELF Matrix TGF- Lumican Cytokeratin-18 Biomarkers Cytokines: VEGF, © IP-10 Osteopontin 20 2014 Biomarkers (Enhanced metalloproteinase-1, Endothelin-1 Galectin INF-, associated (M30 Liver for Therapeutics IL-6, Assessing and Fibrosis) with IL-8, M65 fibrosis NASH—ballooning NASH -3, TNF-, NASDAQ:
Slide 21: Phase 2 Clinical Trial Plans
Phase Patient Treatment Primary FDA-AASLD Galectin Secondary Liver Serum © 21 2014 Biopsy: 2biomarkers inclusion: Galectin Clinical endpoint: human Duration: endpoints: NASH NASH NASH Trial Therapeutics Biopsy Liver based 6-12 Activity Plans endpoints biopsy biopsy: on proven months analysis Score N
Slide 22: Competition
Competition Most FLINT PIVENS Few Galectin: Gilead: Initiated Top © 22 2014 line companies drugs trial Lysyl Galectin data Phase GR-MD-02 in (NIDDK in Q3 oxidase-like-2 development 2NASH currently Therapeutics trials 2015andin 2012 have Intercept) focus mAb NASDAQ:GALT in programs patients on (GS-66
Slide 23: Fibrosis Strategy Summary
Fibrosis NASH Lung Kidney Ongoing Discussions © 23 2014 fibrosis with fibrosis Galectin Strategy discussions Advanced will – pre-clinical provide Therapeutics Summary with Fibrosis: foundation large results NASDAQ:GALT pharmaceutical Evidence suggest for partnering of possible efficacy companies opp
Slide 24: The Agenda
The Agenda Cancer © Summary 24 2014 Company Immunotherapy Galectin andTherapeutics Key Team Members NASDAQ:GALT Galectin Inhibitors Fibrosis Program – our key focus
Slide 25: Cancer Immunotherapy: Checkpoint Inhibitors
May “We Checkpoint Wednesday. CTLA4 Marketed: In Anti-PD-1 Anti Cancer © 25 2014 Development: believe PD-L1 22,Immunotherapy immunotherapy Galectin receptor 2013 (nivolumab Inhibitor (MPDL3280A this market Therapeutics mAb:Blockade BMS; Yervoy® drugs Named will, Roche) generate lambrolizumab will NA
Slide 26: Galectins Have Multiple Roles in Tumor Pathogenesis
The Metastasis: Tumor Angiogenesis © 26NASDAQ:GALT 26 2014 NASDAQ:GALT Vast cell immunity Galectin Majority invasion: cell invasion Therapeutics has of extracellular Cancers recently and migration Secrete beenmatrix shown Large adhesion toAmounts be critically & detachment of Galectins affected by W
Slide 27: Cancer Focus: Metastatic Melanoma
Cancer Focus Metastatic In 5% Even We Demonstrated Tumor Ability Two Ludwig Robert © 27 2014 US NASDAQ:GALT have five collaborations with 76,000 on immunology W. Therapy to Galectin Cancer year sought cancer conduct Franz newly melanoma survival new clinical Institute, collaborations Strategy immuno
Slide 28: Potential Immunotherapies with Galectin Inhibitors
Potential Immunotherapies CD8+ inhibitors 28 28NASDAQ:GALT T-Cells sites to enhance of + Galectin-3 action Checkpoint anti-tumor for galectin Tumor Inhibitor activity Clonal inhibition Blockage: ofCells T-cells inGalectin-3 tumor anti-CTLA4 by blocking immunology Expansion anti-PD1 “Galectin T-Cells
Slide 29: Exploratory Metastatic Melanoma Clinical Trial Design
Exploratory Metastatic Design Eight 2No treatment patients was patients melanoma 29NASDAQ:GALT Enrollment Introduction The © 2014 Ludwig to Clinical emergent Galectin in screened, prime with Institute ofthe Trial Yervoypatients trial, mixed AE’s 6 and patients Therapeutics study does ®hasat funded L
Slide 30: Collaboration and Pre-clinical Results
Collaboration Pre-clinical In mouse Important These © 30NASDAQ:GALT 2014 tumor results cancer Galectin bearing toresults studies note have models established Therapeutics animals, that led demonstrate show GM-CT-01 to decision galectin in the2012 combination that did inhibitors to with treatment ini
Slide 31: Checkpoint Inhibitor Combination with GR-MD-02
Checkpoint aCTLA-4 *p<0.05 Unpublished © 31 2014 NASDAQ:GALT Galectin = inhibitor anti-CTLA-4 dataTherapeutics 2013: blockage Stefanie mAbplus [ipilimumab N.GR-MD-02 Linch, Melissa in humans boosts J. Kasiewicz, anti-tumor (Yervoy, BMS)] Peter immunity G. aPD-1 Traber, in syngeneic = anti-PD-1 and W
Slide 32: Initiation of Phase 1B Trial in Melanoma
Initiation The Patients 3+3 Tumor Endpoints Biological Initial © 32 2014 NASDAQ:GALT Providence phase funding response Galectin with of1responses adesign advanced Phase ofPortland Therapeutics clinical with 1B including melanoma study dose Medical trial escalation of by memory patients PPMC/EACRI. C
Slide 33: Cancer Therapy Strategy Summary
Cancer Two Our Providence combination Ongoing © 33 2014 NASDAQ:GALT strategy immunotherapy Therapy Galectin discussions Portland is of to Yervoy Strategy: Therapeutics leverage Medical with agents andSummary large world GR-MD-02 have Center pharmaceutical class beenand expertise approved Earle A. co
Slide 34: The Agenda
The Agenda Galectins Fibrosis Cancer © Summary 34 2014 NASDAQ:GALT Company Immunotherapy Galectin Program and Disease andTherapeutics –Key our key Teamfocus Members
Slide 35: Summary
Summary Liver First Phase Other Cancer Leverage Ongoing © 35 2014 NASDAQ:GALT indication: Fibrosis Organ 1Therapy: Galectin clinical discussions world of Development Fibrosis: trial class GR-MD-02 Therapeutics Combination underway; with expertise Studies large Program into immunotherapy NASH in phar
Galectin Therapeutics — Investor Presentation (January 2014) on 6ix